Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha.
BACKGROUND
Temsirolimus was approved in Europe as first-line treatment of poor-prognosis advanced renal cell carcinoma (advRCC) based on significant clinical benefits.


METHODS
Patients with advRCC and multiple poor-prognostic factors were randomly assigned to receive 25 mg intravenous temsirolimus weekly, interferon-alpha (titrated to 18 mU) three times weekly, or 15 mg intravenous temsirolimus weekly plus 6 mU of interferon-alpha three times weekly. EuroQol-5D utility score (EQ-5D index) and the EQ-5D visual analogue scale (EQ-VAS) responses were recorded. For analysis, patients were required to have their EQ-5D data recorded at baseline, week 12, and last visit after week 12. The analysis was conducted using last-visit data and a repeated-measures mixed-effect (RMME) model to evaluate quality-of-life differences between temsirolimus and interferon-alpha, controlling for baseline covariates.


RESULTS
Average EQ-5D score at the last measure was significantly higher in patients receiving temsirolimus compared with interferon-alpha: by 0.10 on EQ-5D index (P=0.0279) and by 6.61 on EQ-VAS (P=0.0095). In the RMME model, the least-square mean for on-treatment EQ-5D index score was 0.590 with temsirolimus and 0.492 with interferon-alpha (P=0.0022).


CONCLUSIONS
Temsirolimus is associated with significantly higher EQ-5D scores compared with interferon-alpha in patients with previously untreated poor-prognosis advRCC.
Yang
S
S
Global Access, Pfizer, Collegeville, Pennsylvania, USA.
de Souza
P
P
Alemao
E
E
Purvis
J
J
D000203:Activities of Daily Living; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000523:psychology; D006304:Health Status; D006801:Humans; D007371:Interferon-gamma / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000523:psychology; D011788:Quality of Life; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives*
D000970:Antineoplastic Agents; C401859:temsirolimus; D007371:Interferon-gamma; D020123:Sirolimus
Arch Gen Psychiatry. 2004 Mar;61(3):310-7
14993119
Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006017
18425931
N Engl J Med. 2007 Jan 11;356(2):185-7
17215538
J Clin Oncol. 1999 Aug;17(8):2530-40
10561319
Pharmacoeconomics. 2010;28(7):577-84
20550223
Qual Life Res. 2004 Sep;13(7):1247-53
15473503
Qual Life Res. 2004 Mar;13(2):311-20
15085903
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
18287387
N Engl J Med. 2007 May 31;356(22):2271-81
17538086
Cancer. 2007 Jul 1;110(1):196-202
17546575
Health Policy. 1990 Dec;16(3):199-208
10109801
Eur J Health Econ. 2003 Sep;4(3):222-31
15609189
Med Care. 1997 Nov;35(11):1095-108
9366889
Eur J Cancer Prev. 2002 Apr;11(2):171-8
11984136
Health Policy. 1996 Jul;37(1):53-72
10158943
Anticancer Drugs. 2005 Aug;16(7):709-17
16027518
N Engl J Med. 2007 Jan 11;356(2):115-24
17215529
J Clin Oncol. 2008 Aug 1;26(22):3763-9
18669464
J Clin Oncol. 2005 Feb 1;23(4):832-41
15681528
J Anim Sci. 1998 Apr;76(4):1216-31
9581947
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
10655437
Lancet. 2008 Aug 9;372(9637):449-56
18653228
J Clin Oncol. 2002 Jan 1;20(1):289-96
11773181
Health Qual Life Outcomes. 2007 Dec 21;5:70
18154669